University of New Hampshire

School of Law

School of Law

W. Nicholson Price II - Biography

Why are large, biologic drugs like Enbrel and Humira so expensive, and likely to stay that way? UNH Law’s Nicholson Price and co-author Arti Rai, from Duke Law, argue that trade-secret manufacturing methods coupled with FDA definitions are hindering competition and reducing the creation of fundamental knowledge about these drugs. Their perspective appeared in Science last week. - April '15

Assistant Professor of Law
Phone info. forthcoming
Biography in brief >>


JD, Columbia University School of Law
PhD, Columbia University Graduate School of Arts and Sciences
AB, Harvard College


(information forthcoming)


Health Law
Patent Law


W. Nicholson Price was an Academic Fellow at Harvard Law School’s Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. He also clerked for Judge Carlos T. Bea of the US Court of Appeals for the Ninth Circuit, and was a Visiting Consortium Scholar at the UCSF/UC Hastings Consortium on Law, Science and Health Policy. At Columbia Law, he served as Submissions Editor of the Columbia Science and Technology Law Review.

Price’s current scholarship is focused on the role of innovation policy in pharmaceutical manufacturing, and on a variety of issues related to genetic testing and genetic sequencing, including the role of gene patents and the return of individual results in genetic research.

Representative Publications:

Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing, 55 B.C.L. Rev. 491 (2014)

Unblocked Future: Why Gene Patents Won’t Hinder Whole-Genome Sequencing and Personalized Medicine, 33 Cardozo L. Rev. 1601 (2012)

Am I My Son? Human Clones and the Modern Family, 11 Colum. Sci. & Tech L. Rev. 118 (2010)